Kymera Therapeutics is a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients.
Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins.
Kymera was founded in 2017 by Nello Mainolfi and Bruce Booth. The company is headquartered in Cambridge, Massachusetts.
Kymera has created Pegasus™, a game-changing integrated degradation platform, which is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics.
Kymera received a strategic investment from The Leukemia & Lymphoma Society‘s Therapy Acceleration Program® (LLS TAP) directed toward advancing the company’s work to treat blood-based cancers.
Kymera is backed by Pfizer Venture Investments, Biotechnology Value Fund (BVF), Wellington Management Company, Bain Capital Life Sciences, Redmile Group and others. The company raised $102M in a Series C round on Mar 12, 2020. This brings Kymera's total funding to $197M to date.